5-MAPBT (5-methylaminopropylbenzothiophene) is an empathogenic drug of the benzothiophene group. It is closely related to 5-MAPB but with the oxygen atom replaced by sulfur, changing the core ring structure to benzothiophene rather than benzofuran.[2]

It has been patented by Tactogen as an entactogen for potential use as a medicine.[2]

See also

References

  1. ^ Mydecine (5 January 2024). "Novel short-acting psychoactive compounds of the mdma class". Google Patents. Retrieved 23 October 2024.
  2. ^ a b WO 2022/010937, Baggott M, "Advantageous benzothiophene compositions for mental disorders or enhancement.", published 13 January 2022, assigned to Tactogen Inc. 
Allikas: https://en.wikipedia.org/wiki/5-MAPBT
No tags for this post.